WO2017103258A1 - Synthèse du dota - Google Patents

Synthèse du dota Download PDF

Info

Publication number
WO2017103258A1
WO2017103258A1 PCT/EP2016/081705 EP2016081705W WO2017103258A1 WO 2017103258 A1 WO2017103258 A1 WO 2017103258A1 EP 2016081705 W EP2016081705 W EP 2016081705W WO 2017103258 A1 WO2017103258 A1 WO 2017103258A1
Authority
WO
WIPO (PCT)
Prior art keywords
carried out
dota
crystallising
acid
halo
Prior art date
Application number
PCT/EP2016/081705
Other languages
English (en)
Inventor
Andreas Richard MEIJER
Arne Wang AABYE
Khalid Hussain
Sondre NILSEN
Mikkel jAC THANING
Jarle Andre HAUGAN
Ingvil GAUSEMEL
Nikolai ENES
Silalahi SUMIHAR
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3008703A priority Critical patent/CA3008703A1/fr
Priority to US16/062,205 priority patent/US10941124B2/en
Priority to AU2016369464A priority patent/AU2016369464B2/en
Priority to KR1020187020165A priority patent/KR20180095001A/ko
Priority to EP16816670.0A priority patent/EP3390373B1/fr
Priority to BR112018012314-5A priority patent/BR112018012314B1/pt
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Priority to ES16816670T priority patent/ES2970245T3/es
Priority to RU2018122071A priority patent/RU2730519C2/ru
Priority to CN201680082109.1A priority patent/CN108699012B/zh
Priority to JP2018531560A priority patent/JP2018537506A/ja
Publication of WO2017103258A1 publication Critical patent/WO2017103258A1/fr
Priority to JP2023116410A priority patent/JP2023153826A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B41/00—Formation or introduction of functional groups containing oxygen
    • C07B41/06—Formation or introduction of functional groups containing oxygen of carbonyl groups
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation

Definitions

  • the present invention relates to the field of magnetic resonance imaging (MRI) and to the synthesis of compounds useful in contrast-enhanced MRI.
  • the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyc lododecane- 1,4,7,10-tetraacetic acid (DOTA) and metal chelates thereof.
  • DOTA 1,4,7,10-tetraazacyc lododecane- 1,4,7,10-tetraacetic acid
  • 1,4,7,10-tetraazacyc lododecane- 1,4, 7, 10-tetraacetic acid is an organic compound consisting of a central 12-membered tetraaza ring of the following structure:
  • DOTA is used as a complexing agent, especially for lanthanide ions, and its complexes have medical applications as cancer treatments and in in vivo imaging and diagnosis.
  • DOTA When used as part of cancer therapies it typically functions as a chelating agent for the radioisotope 90 Y 3+ .
  • DOTA can also be conjugated to monoclonal antibodies by attachment of one of the four carboxyl groups as an amide. The remaining three carboxylate anions bind to the yttrium ion. Modified antibody accumulates in tumour cells, concentrating the effects of the radioactivity of 90 Y. Drugs containing this module receive an International Nonproprietary Name ending in "tetraxetan”.
  • DOTA also forms particularly stable chelates with contrast-generating paramagnetic metal ions and especially those that are lanthanide ions.
  • the gadolinium-DOTA chelate Dotarem ® is one commercially available MRI agent.
  • DOTA obtained from this reaction is contaminated with organic impurities and inorganic salts and as a consequence requires purification to be of use in the manufacturing of a pharmaceutical contrast agent.
  • the most common inorganic salt that is present in crude DOTA is sodium chloride. Purification is typically carried out by crystallization of the reaction mixture at a very low pH to obtain DOTA with reduced levels of impurities. A very low pH permits DOTA to be obtained with very low levels of sodium.
  • the chloride impurities are typically removed by purification with ion exchange resin.
  • EP0998466 Bl (Bracco) describes a DOTA synthetic process including the steps:
  • WO2013076743 (Biophore) describes a DOTA synthetic process consisting of:
  • step 2) Purification of the material obtained in step 2) by adsorption to cationic resin and then desorbing DOTA with a volatile base solution.
  • step 4) Purification of the material obtained in step 3) by adsorption to anionic resin and then firstly washing with a dilute organic volatile acid and secondly desorbing DOTA by washing with a concentrated volatile acid.
  • WO2014055504 (Mallinckrodt) describes a DOTA synthetic process consisting of:
  • the present invention provides a method for the synthesis of 1,4,7,10- tetraazacyclododecane- 1,4,7,10-tetraacetic acid (DOTA) wherein said method comprises:
  • step (b) crystallising the reaction mixture obtained in step (a) wherein said
  • crystallising is carried out at a pH >3 and ⁇ 3.5;
  • step (c) filtering an aqueous solution of the crystallised product of step (b) using membrane filtration;
  • step (d) crystallising the filtered solution obtained in step (c).
  • the present invention provides a method for preparing a metal- DOTA chelate of Formula (I) or Formula (II):
  • said method comprises treating the product obtained according to the method of the first aspect of the invention with a metal cation, M n+ , wherein n+ is 2 or 3, provided from a metal ion source selected from the group consisting of metal oxides, metal carbonates, and weak chelates and wherein the metal cation is selected from the group consisting of Gd, Eu, Tb, Dy, Sm, Lu, La, In, Ga, Re, Ru, Fe, Cu, Zn, Ni, Co, Cr, V, Ti, Sc, Zr, Nb, Mo, Rh, Pd, Ag, Cd, Sn, Hf, Ta, W, Os, Ir, Pt, Au and Y, and wherein M 2+ coordination can occur with any two of the carboxyl moieties.
  • the present invention provides a method for preparing gadoterate meglumine comprising:
  • the methods of the present invention are particularly suitable for industrial
  • the DOTA obtained by the methods of the present invention is characterised by very low levels of organic and inorganic impurities.
  • reacting refers to the synthetic reaction between cyclen and a halo-acetic acid to form DOTA.
  • the product of the reacting is a crude reaction mixture comprising DOTA and various impurities.
  • base refers to a substance that accepts protons from any proton donor and/or contains completely or partially displaceable OFT ions.
  • crystalising refers to a purification method that separates a product from a liquid feedstream either by cooling the feedstream or adding precipitants which lower the solubility of the desired product so that it forms crystals.
  • filtering refers to the purification method for the separation of solids from fluids (liquids or gases) by interposing a medium through which only the fluid can pass.
  • the fluid that passes through is called the filtrate.
  • membrane filtration refers to a method of filtration that separates components of a mixture from the rest of the mixture by permeation through membranes of different pore sizes.
  • said halo-acetic acid is selected from the group comprising iodoacetic acid, bromoacetic acid and chloroacetic acid. In one embodiment said halo-acetic acid is chloroacetic acid. In one embodiment said halo- acetic acid is the salt of said halo-acetic acid, e.g. the potassium salt or the sodium salt. In one embodiment said halo-acetic acid is potassium chloroacetate or sodium chloroacetate. In one embodiment of the method of the invention said base is selected from the group comprising an alkali hydroxide or an alkaline-earth metal hydroxide. In one
  • said base is an alkali hydroxide. In one embodiment said base is NaOH or KOH. In one embodiment said base is NaOH. In another embodiment of the method of the invention said base is KOH. In one embodiment of the method of the invention step (a) is carried out at pH 9.0-12.5. In one embodiment said step (a) is carried out at pH 9.5-12.0. In one embodiment said step (a) is carried out at pH 10.0-11.5. In one embodiment said step (a) is carried out at pH 10.5-11.5. In one embodiment said step (a) is carried out at a pH of around 11.
  • the term "pH of around 11" is intended to encompass pH 11 and small variations around pH 11. For example the ranges pH 10.75-11.25, pH 10.8-11.2 and pH 10.9-11.1 can be considered as embodiments of the term "pH of around 11".
  • step (b) is adjusted by addition of an acid selected from the group comprising HC1, H2SO4, HNO3, HBr, HCIO4 and HI. In one embodiment the pH in step (b) is adjusted by addition of HC1. Monitoring and adjusting pH during alkylation and filtration may be carried out manually or in an automated fashion.
  • step (b) comprises addition of an organic solvent to the reaction mixture obtained from step (a).
  • said organic solvent is a short-chain alcohol, e.g. ethanol or methanol.
  • said organic solvent is acetone.
  • said filtering step (c) is carried out by electrodialysis.
  • electrolysis can be understood to be a membrane filtration process during which ions are transported through a semi-permeable membrane under the influence of an electric potential.
  • the membrane can be either cation- or anion-selective such that either positive ions or negative ions selectively flow through.
  • said filtering step (c) is carried out by nano filtration.
  • nano filtration as used herein is taken to mean a membrane filtration process whereby the membrane comprises pores of a size suitable for the separation of small molecules and ions from larger (organic) molecules. Typical pore sizes for nano filtration are in the range generally 1-10 nanometers.
  • steps (b), (c) and (d) are
  • pH 3-4 independently carried out between pH 3-4, for example at pH 3-3.5 or at pH 3.2.
  • step (d) comprises addition of an organic solvent to the reaction mixture obtained from step (c).
  • said organic solvent is a short-chain alcohol, e.g. ethanol, isopropanol or methanol.
  • step (b) crystallising the reaction mixture obtained in step (a) wherein said
  • crystallising comprises addition of methanol and is carried out at pH 3-4, e.g. pH 3.2, and wherein the pH is adjusted by addition of HC1;
  • step (c) filtering an aqueous solution of the crystallised product of step (b) by electrodialysis or by nano filtration;
  • step (d) crystallising the filtered solution obtained in step (c) wherein said
  • crystallising comprises addition of methanol and is carried out at pH 3-4, e.g. pH 3.2, and wherein the pH is adjusted by addition of HC1.
  • Step (a) may be carried out using methods known in the art for example as set out by Desreux (1980 Inorganic Chemistry; 19(5): 1319-1324) and by Delgado (1982 Talanta; 29(10): 815-822). Crystallisation techniques are well known to those of skill in the art and text books are available describing different methods (see for example "Crystallization: Basic
  • Both crystallisation steps of the method of the present invention start with an aqueous solution from the immediate preceding step.
  • Step (a) of reacting cyclen with a halo- acetic acid as defined herein is done in an aqueous solution.
  • Step (c) of filtering is carried out on an aqueous solution that is then concentrated to a particular aqueous concentration prior to step (d).
  • each of crystallisation step (b) and filtration step (c) of the method of the invention is important in order to get a good purification and therefore a good yield of DOT A. pH values below 3 or above 3.5 may impact removal of sodium ions, which are mainly removed in steps (b) and (c).
  • step (c) in order for the positive ion Na + to cross the membrane a negative ion is required and this is provided in one embodiment as CI " in HC1.
  • Example 1 describes a method to obtain DOTA according to a non- limiting
  • Methanol content was assessed by GC.
  • the above crude DOTA was dissolved in water and subjected to nano filtration, whereby the sodium content was reduced from 2.5 w% to 1.3 w%.
  • An aqueous solution of this reduced salt DOTA was dissolved in water, the solution concentrated and then methanol added to induce crystallisation and remove the remaining sodium chloride.
  • the isolated crystals had a much lower sodium content (0.0 - 0.3 w%>,), with ca. 4 w% methanol.
  • the above crude DOTA was dissolved in water and sampled for measurement of quantity and sodium content (369 kg DOTA; 87 % yield; 5.26 % Na) and subjected to nano filtration whereby the sodium content was reduced from 5.26 w% to 0.84 w%.
  • the aqueous solution this reduced salt DOTA was concentrated and then methanol added to induce crystallization and remove the remaining sodium chloride.
  • the isolated crystals had a sodium content NMT 10 ⁇ g/g DOTA.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de préparation de composés utiles dans des applications thérapeutiques et diagnostiques in vivo. En particulier, la présente invention concerne un procédé de synthèse d'acide 1,4,7,10-tétraazacyclododécane-1,4,7,10-tétraacétique (DOTA), ainsi que des procédés pour la préparation de chélates métalliques du DOTA.
PCT/EP2016/081705 2015-12-18 2016-12-19 Synthèse du dota WO2017103258A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US16/062,205 US10941124B2 (en) 2015-12-18 2016-12-19 DOTA synthesis
AU2016369464A AU2016369464B2 (en) 2015-12-18 2016-12-19 DOTA synthesis
KR1020187020165A KR20180095001A (ko) 2015-12-18 2016-12-19 Dota 합성
EP16816670.0A EP3390373B1 (fr) 2015-12-18 2016-12-19 Synthèse de la dota
BR112018012314-5A BR112018012314B1 (pt) 2015-12-18 2016-12-19 Método para síntese de ácido, e, métodos para preparar um quelato de dota metálico e gadoterato de meglumina
CA3008703A CA3008703A1 (fr) 2015-12-18 2016-12-19 Synthese et epuration du dota
ES16816670T ES2970245T3 (es) 2015-12-18 2016-12-19 Síntesis de dota
RU2018122071A RU2730519C2 (ru) 2015-12-18 2016-12-19 Синтез DOTA
CN201680082109.1A CN108699012B (zh) 2015-12-18 2016-12-19 Dota合成
JP2018531560A JP2018537506A (ja) 2015-12-18 2016-12-19 Ｄｏｔａ合成
JP2023116410A JP2023153826A (ja) 2015-12-18 2023-07-18 Ｄｏｔａ合成

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522412.4A GB201522412D0 (en) 2015-12-18 2015-12-18 Dota synthesis
GB1522412.4 2015-12-18

Publications (1)

Publication Number Publication Date
WO2017103258A1 true WO2017103258A1 (fr) 2017-06-22

Family

ID=55311244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/081705 WO2017103258A1 (fr) 2015-12-18 2016-12-19 Synthèse du dota

Country Status (12)

Country Link
US (1) US10941124B2 (fr)
EP (1) EP3390373B1 (fr)
JP (3) JP2018537506A (fr)
KR (1) KR20180095001A (fr)
CN (1) CN108699012B (fr)
AU (1) AU2016369464B2 (fr)
BR (1) BR112018012314B1 (fr)
CA (1) CA3008703A1 (fr)
ES (1) ES2970245T3 (fr)
GB (1) GB201522412D0 (fr)
RU (1) RU2730519C2 (fr)
WO (1) WO2017103258A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601792A (zh) * 2018-01-19 2020-08-28 株式会社Enzychem生命科学 生产考布曲钙的方法
US10941124B2 (en) 2015-12-18 2021-03-09 Ge Healthcare As DOTA synthesis
WO2021250163A1 (fr) 2020-06-10 2021-12-16 Justesa Imagen S.A.U. Procédé d'obtention de gadotérate de méglumine à partir de tétraxetan (dota) de haute pureté et son utilisation dans la préparation de formulations galéniques injectables

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113087680A (zh) * 2020-01-08 2021-07-09 威智医药有限公司 Dota晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076743A2 (fr) * 2011-11-25 2013-05-30 Biophore India Pharmaceuticals Pvt. Ltd. Procédé de purification de polyaminocarboxylates
WO2014055504A1 (fr) * 2012-10-02 2014-04-10 Mallinckrodt Llc Processus de préparation de ligands et chélates polyazacarboxylates macrocycliques
WO2015117911A1 (fr) * 2014-02-06 2015-08-13 Agfa Healthcare Procédé de purification d'acide 1,4,7,10-tétraazacyclododécane-1,4,7,10-tétraacétique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
NO20051911D0 (no) 2005-04-19 2005-04-19 Amersham Health As Synthesis
CN102659702B (zh) * 2012-04-09 2014-12-03 武汉工程大学 一种1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸的纯化方法
US9458117B2 (en) * 2013-01-28 2016-10-04 Agfa Healthcare Nv Process for producing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and complexes thereof
GB201522412D0 (en) 2015-12-18 2016-02-03 Ge Healthcare As Dota synthesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076743A2 (fr) * 2011-11-25 2013-05-30 Biophore India Pharmaceuticals Pvt. Ltd. Procédé de purification de polyaminocarboxylates
WO2014055504A1 (fr) * 2012-10-02 2014-04-10 Mallinckrodt Llc Processus de préparation de ligands et chélates polyazacarboxylates macrocycliques
WO2015117911A1 (fr) * 2014-02-06 2015-08-13 Agfa Healthcare Procédé de purification d'acide 1,4,7,10-tétraazacyclododécane-1,4,7,10-tétraacétique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SORIN A ET AL: "Polyaminocarboxylic acids rejection by charged nanofiltration membrane", JOURNAL OF MEMBRANE SCIENCE, ELSEVIER BV, NL, vol. 279, no. 1-2, 1 August 2006 (2006-08-01), pages 446 - 452, XP024931534, ISSN: 0376-7388, [retrieved on 20060801], DOI: 10.1016/J.MEMSCI.2005.12.037 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10941124B2 (en) 2015-12-18 2021-03-09 Ge Healthcare As DOTA synthesis
CN111601792A (zh) * 2018-01-19 2020-08-28 株式会社Enzychem生命科学 生产考布曲钙的方法
JP2021511332A (ja) * 2018-01-19 2021-05-06 エンジーケム ライフサイエンシーズ コーポレイション カルコブトロールの製造方法
JP7071760B2 (ja) 2018-01-19 2022-05-19 エンジーケム ライフサイエンシーズ コーポレイション カルコブトロールの製造方法
CN111601792B (zh) * 2018-01-19 2023-10-20 株式会社Enzychem生命科学 生产考布曲钙的方法
WO2021250163A1 (fr) 2020-06-10 2021-12-16 Justesa Imagen S.A.U. Procédé d'obtention de gadotérate de méglumine à partir de tétraxetan (dota) de haute pureté et son utilisation dans la préparation de formulations galéniques injectables

Also Published As

Publication number Publication date
EP3390373C0 (fr) 2023-12-13
US10941124B2 (en) 2021-03-09
BR112018012314B1 (pt) 2022-07-26
JP2021183615A (ja) 2021-12-02
EP3390373A1 (fr) 2018-10-24
BR112018012314A2 (pt) 2018-12-04
AU2016369464B2 (en) 2020-12-03
CN108699012B (zh) 2022-08-02
JP2023153826A (ja) 2023-10-18
KR20180095001A (ko) 2018-08-24
AU2016369464A1 (en) 2018-07-05
US20180370925A1 (en) 2018-12-27
JP2018537506A (ja) 2018-12-20
CN108699012A (zh) 2018-10-23
RU2730519C2 (ru) 2020-08-24
RU2018122071A (ru) 2020-01-20
GB201522412D0 (en) 2016-02-03
RU2018122071A3 (fr) 2020-01-30
EP3390373B1 (fr) 2023-12-13
CA3008703A1 (fr) 2017-06-22
ES2970245T3 (es) 2024-05-27

Similar Documents

Publication Publication Date Title
AU2016369464B2 (en) DOTA synthesis
CN106187930B (zh) 高纯度考布曲钙的制备方法
RU2707070C2 (ru) Композиции, содержащие комплексы металлов ряда лантаноидов
CN108047151A (zh) 一种高收率钆布醇的制备方法
JP2017538685A (ja) 金属錯体製剤
WO2011054480A1 (fr) Préparation de gadobutrol au moyen d'une membrane céramique
JP2010022886A (ja) テトラフルオロホウ酸イオンの除去方法
CN103467466A (zh) 一种盐酸莫西沙星杂质的合成方法
EP3733651A1 (fr) Procédé de préparation de calcobutrol
DE102010013833A1 (de) Herstellung von Gadobutrol mittels Dimethylformamiddimethylacetal
CN106220580B (zh) 钆特酸葡胺的提纯方法
JP5954829B2 (ja) カプセル型化合物、陰イオン除去剤、及び陰イオン除去方法
CN113272284B (zh) 制备考布曲钙的方法
WO2017082430A1 (fr) Fluorescéine sodique de grande pureté
CN111375071B (zh) 一种制备造影剂方法
CN112574131A (zh) 一种dota的纯化方法
CN109384737A (zh) 一种四氮杂环钇络合物及其制备方法和应用
JP2023015909A (ja) ジルコニウムの精製方法
CN115916761A (zh) 利用高纯度四西坦(dota)制取钆特酸葡甲胺的方法及其在制备可注射盖仑制剂中的应用
CN113087680A (zh) Dota晶型及其制备方法
DE102009057274B4 (de) Gadobutrolherstellung mittels Trioxobicyclo-octan
TR2021010179T2 (tr) Kalkobutrol hazirlamaya yöneli̇k yöntem
JP2014527998A (ja) 純粋なＳ−（−）−９−フルオロ−６，７−ジヒドロ−８−（４−ヒドロキシピペリジン−１−イル）−５−メチル−１−オキソ−１Ｈ，５Ｈ−ベンゾ［ｉ，ｊ］キノリジン−２−カルボン酸Ｌ−アルギニン塩４水和物およびその製造方法
CN108218765A (zh) 一种改进盐酸马尼地平ii晶型的生产方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16816670

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3008703

Country of ref document: CA

Ref document number: 2018531560

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018012314

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016369464

Country of ref document: AU

Date of ref document: 20161219

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187020165

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020187020165

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2018122071

Country of ref document: RU

Ref document number: 2016816670

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112018012314

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180615